PHILIPS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139 BRL | -2.17% |
|
0.00% | +24.77% |
| 06-28 | PHILIPS NV : JP Morgan reiterates its Neutral rating | ZD |
| 06-27 | Chinese-owned chipmaker Nexperia invests $200 mln in European expansion | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 117.99 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +24.77% | 23.58B | - | ||
| +4.18% | 211B | B | ||
| +8.00% | 185B | B- | ||
| +31.86% | 158B | B- | ||
| +33.21% | 113B | A- | ||
| +2.28% | 64.32B | A- | ||
| +21.14% | 55.66B | B+ | ||
| +0.11% | 48.41B | B+ | ||
| -6.76% | 37.82B | A | ||
| +0.78% | 35.57B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PHIA Stock
- PHGN34 Stock
- Ratings Philips NV
